

Bexel Pharmaceuticals, Inc.
Balance Sheet at at March 31, 2024 (Provisional)

	March 31, 2024
ASSETS	
Current Assets	
Checking/Savings	
1010 · WFB #0131 - New Checking	5.00
1000 · WFB #4602 - Old Checking	0.00
Total Checking/Savings	5.00
Other Current Assets	
1620 · Receivable - Orchid	0.00
Total Other Current Assets	0.00
Total Current Assets	5.00
Fixed Assets	
1100 · Laboratory Equipment	
1101 · Laboratory Equip-Accum Depreciation	-8,886.78
1102 · Laboratory Equipment Cost	8,886.78
Total 1100 · Laboratory Equipment	0.00
1200 · Computers and Office Equip	
1201 · Computers-Accum Depreciation	-20,976.08
1202 · Computers Cost	20,976.08
Total 1200 · Computers and Office Equip	0.00
Total Fixed Assets	0.00
TOTAL ASSETS	5.00
LIABILITIES & EQUITY	
Liabilities	
Current Liabilities	
Other Current Liabilities	
2100 · Payroll Liabilities	1,27,169.05
2170 · Retirement Fidelity FPRS	2.20
Total Other Current Liabilities	1,27,171.25
Total Current Liabilities	1,27,171.25
Long Term Liabilities	
2135 · Due to OrchidPharma, Inc.	49,989.00
2130 · Intercompany - Orchid	54,71,500.00
Total Long Term Liabilities	55,21,489.00
Total Liabilities	56,48,660.25
Equity	
3100 · Common Stock	21,002.02
3150 · Preferred Stock	10,000.00
3160 · Series B Preferred	4,893.25
3200 · Additional Paid in Capital	1,83,38,881.27
3400 · Treasury Stock	-13,00,460.94
3900 · Retained Earnings	-2,27,22,970.85
Total Equity	-56,48,655.25
TOTAL LIABILITIES & EQUITY	5.00

BEXEL Pharmaceuticals, Inc.
Profit & Loss
April 2023 through March 2024

	Accrual Basis
	Apr' 23 - Mar' 24
Net Income	0.00
<u>Expenses</u>	
Bank Charges	0.00
IRS Charges	0.00
	0.00
Net Loss for the period	0.00